Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

The U.S. Food and Drug Administration (FDA) on Friday approved Sanofi SA’s SNY subcutaneous Sarclisa Escena (isatuximab-irfc) ...

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference ® (AAIC ®) 2026 in London support that the LEQEMBI ® ...

Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...

Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. Seventy-three patients were given CdA as a subcutaneous injection once daily for 7 days. Complete remission (CR) ...

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class ...

Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last ...